Amyloid monomeric proteins can sometimes oligomerize into destructive amyloid fibrils. Amyloidogenic conformations of non-disease related proteins can be created by partial protein misfolding or denaturation. In disease state oligomerization, extensive amyloid oligomerization creates plaques in neural tissue that correlates with Alzheimer’s symptomology.
Recognizes amyloid oligomer. The antibody recognize all types of amyloid oligomers. The antibody appears to recognize a peptide backbone epitope that is common to amyloid oligomers, but is not found in native proteins, amyloidogenic monomer or mature amyloid fibrils. This antibody has been referred to as A11.
Anti-Amyloid Oligomer Antibody, αβ, oligomeric is an antibody against Amyloid Oligomer for use in ELISA, IF, IH, IH(P), IP & WB.
Research Sub Category
A 1:1,000-1:10,000 concentration was used on a previous lot.
A 1:1,000 concentration was used on a previous lot. Suggested cell lysis buffer is RIPA. Suggested capture agent is magnetic beads (Dynabeads). Known co-precipitatiing polypeptide: Amyloid beta, alpha synuclein oligomers.
A previous lot of this antibody was used in ELISA.
Optimal working dilutions must be determined by the end user.
Evaluated by Western Blot on mouse brain lysates.
Western Blotting Analysis:
1:500 dilution of this antibody detected AMYLOID OLIGOMER on 10 μg of mouse brain lysates.
Rabbit Serum. Contains no preservative.
Storage and Stability
Stable for 1 year at -20ºC from date of receipt.
Concentration: Please refer to the Certificate of Analysis for the lot-specific concentration.
CHEMICON is a registered trademark of Merck KGaA, Darmstadt, Germany
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.